Reflection AI is officially unveiling Beam, its first frontier, open-weight AI model. The two-year-old, Brooklyn-based startup claims Beam matches the performance of leading Chinese open models on ...
Generic competition lowers retail prescription drug prices, but little is known about its effect on net prices, accounting for manufacturer rebates. Using data on rebates and discounts for Part D, we ...
Cheap labor and global supply chains are among the obstacles to President Trump’s plan to bring generic drug manufacturing back home. Credit...Video by Harsha Vadlamani Supported by By Alex Travelli ...
AAM’s annual savings report highlights that generic and biosimilar medicines created $496 billion in savings in 2025. Keeton added, “Despite recent wins in overall savings, streamlining and ...
If you take a patented, brand-name medication — a cancer biologic, an autoimmune drug, a specialty injection — the supply chain behind that drug is about to be permanently restructured, starting at 12 ...
Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...
Imported generic drugs could face tariffs of up to 100% beginning in 2028 under a plan announced Tuesday by President Trump, who said the measure is intended to push manufacturers to move production ...
A multiyear “tariff cliff” sets 0% through July 2028, then 100% for one year and 200% thereafter, explicitly tying penalties to failure to establish US manufacturing capacity. Sparse implementation ...
Reflection AI, a U.S. startup vying to develop open models, has signed a $1 billion compute deal with European AI infrastructure company Nebius. Nebius, a company spun out of Russian tech giant Yandex ...
New to the Celebrity fleet is Orange Peel Bar and Grille, offering a menu of grilled options as well as frozen cocktails. Photo Credit: Celebrity Cruises The Celebrity Reflection is getting 13 new ...
The Hikma Court correctly held that a generic manufacturer should not be liable for induced patent infringement if it carves patented uses out of its label. FDA can navigate Hikma’s aftermath without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results